LU101272B1 - Route and engineering protocols for alzheimer's disease prevention, treatment and neuronal rebuilding - Google Patents
Route and engineering protocols for alzheimer's disease prevention, treatment and neuronal rebuilding Download PDFInfo
- Publication number
- LU101272B1 LU101272B1 LU101272A LU101272A LU101272B1 LU 101272 B1 LU101272 B1 LU 101272B1 LU 101272 A LU101272 A LU 101272A LU 101272 A LU101272 A LU 101272A LU 101272 B1 LU101272 B1 LU 101272B1
- Authority
- LU
- Luxembourg
- Prior art keywords
- composition
- generating
- tesla
- composition according
- silicon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (22)
1. Composition comprenant du zinc Zn-FLNT4 et du silicium SiHR57 sous la forme de (3(CH3Si(OH)3-R(COO x)) pour une utilisation comme un médicament ou en thérapie.
2. Composition selon la revendication 1, dans laquelle x est choisi dans le groupe comprenant sodium, potassium et lithium.
3. Composition selon la revendication 1 ou 2, dans laquelle Zn-FLNT4 est associé à une molécule de D-fructose.
4. Composition selon l’une quelconque des revendications 1 à 3, pour une utilisation dans un procédé pour le traitement de maladies neurodégénératives et cardiovasculaires.
5. Composition selon la revendication 4, où le procédé comprend en outre l’utilisation d’une troisième composition comprenant des cyclodextrines (xBy).
6. Composition selon la revendication 4 ou 5, où le procédé comprend en outre l’utilisation d’une quatrième composition comprenant de l’acide ursodésoxycholique.
7. Composition selon l’une quelconque des revendications 4 à 6, où le procédé comprend en outre l’utilisation de cellules souches primaires.
8. Composition selon l’une quelconque des revendications 1 à 7, pour une utilisation dans un procédé pour atténuer une neurodégénérescence associée à une exposition à au moins un élément choisi parmi des particules énergétiques solaires, des rayons cosmiques galactiques et une radiation extra-terrestre.
9. Composition selon la revendication 8, incorporée dans un ou plusieurs complément(s) alimentaire(s) pour l’homme en vue d’une administration.
10. Procédé pour aligner le spin de molécules dans la composition selon la revendication 1, comprenant les étapes consistant à: localiser au moins un conduit adjacent à une source d’ondes radio électromagnétiques (EM-RF); faire circuler la composition à travers le conduit; et générer une EM-RF avec la source, pour soumettre la composition dans le conduit à la EM-RF générée.
11. — Procédé selon la revendication 10, dans laquelle l’étape de génération comprend en outre la génération de la EM-RF avec une intensité dans l’intervalle de 0,05 Tesla à 0,3 Tesla.
12. Procédé selon la revendication 10, dans laquelle l’étape de génération comprend en outre la génération de la EM-RF avec une intensité dans l’intervalle de 1,5 Tesla à 3 Tesla.
-2- LU101272
13. Procédé selon la revendication 11 ou 12, dans laquelle l’étape de génération comprend en outre la génération de la EM-RF comme une EM-RF permanente, une EM- RF modulée par impulsion ou une EM-RF oscillante.
14. Procédé selon l’une quelconque des revendications 10 à 13, comprenant les étapes supplémentaires consistant à: administrer la composition soumise à une EM-RF au patient; localiser au moins une zone du patient incluant la composition administrée adjacente à un appareil d’imagerie par résonance magnétique (IRM); et générer une deuxième EM-RF avec l’appareil IRM, pour soumettre la zone incluant la composition administrée à la deuxième EM-RF générée.
15. Procédé selon la revendication 14, dans laquelle l’étape de génération de la deuxième EM-RF comprend en outre la génération de la deuxième EM-RF avec une intensité dans l’intervalle de 1,5 Tesla à 3 Tesla.
16. Procédé selon l’une quelconque des revendications 10 à 15, dans laquelle l’étape d’administration est effectuée par un moyen choisi parmi ingestion orale, pulvérisation endonasale ou \intranasale, sonde dermique, patch transdermique et injection intrapéritonéale ou intracrânienne.
17. Procédé selon l’une quelconque des revendications 10 à 16, dans laquelle le conduit est une partie d’une seringue à vitesse régulée.
18. Particule de cyclodextrine pour administrer la composition selon la revendication 1.
19. Particule de cyclodextrine selon la revendication 18, où la particule est façonnée comme une cage tridimensionnelle avec au moins une ouverture.
20. Particule de cyclodextrine selon la revendication 18 ou 19, où la particule est façonnée comme un tore.
21. Particule de cyclodextrine selon l’une quelconque des revendications 18 à 20, comprenant en outre des nanoparticules ou des picoparticules de silicium-germanium localisées sur une surface interne de la particule de cyclodextrine.
22. Particule de cyclodextrine selon l’une quelconque des revendications 18 à 21, comprenant en outre du carbonyle de zinc localisé sur une surface externe de la particule de cyclodextrine.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LU101272A LU101272B1 (en) | 2019-06-19 | 2019-06-19 | Route and engineering protocols for alzheimer's disease prevention, treatment and neuronal rebuilding |
IE20200056U IE20200056U1 (en) | 2019-06-19 | 2020-04-07 | NEW ROUTE AND ENGINEERING PROTOCOLS FOR ALZHEIMER’s DISEASE PREVENTION, TREATMENT AND NEURONAL REBUILDING |
US16/906,450 US20210000867A1 (en) | 2019-06-19 | 2020-06-19 | New route and engineering protocols for alzheimers disease prevention, treatment and neuronal rebuilding |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LU101272A LU101272B1 (en) | 2019-06-19 | 2019-06-19 | Route and engineering protocols for alzheimer's disease prevention, treatment and neuronal rebuilding |
Publications (1)
Publication Number | Publication Date |
---|---|
LU101272B1 true LU101272B1 (en) | 2020-12-28 |
Family
ID=67297235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU101272A LU101272B1 (en) | 2019-06-19 | 2019-06-19 | Route and engineering protocols for alzheimer's disease prevention, treatment and neuronal rebuilding |
Country Status (2)
Country | Link |
---|---|
IE (1) | IE20200056U1 (fr) |
LU (1) | LU101272B1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996023089A1 (fr) | 1993-07-23 | 1996-08-01 | Jolinon Monique | Procede de preparation de complexes organometalliques, les applications en tant que medicaments et en catalyses chimiques |
WO2008055684A1 (fr) | 2006-11-08 | 2008-05-15 | Glycan-Pharma (Switzerland) Sa | Procédé de traitement de déchets dangereux utilisant un plasma et dispositif de mise en œuvre du procédé |
WO2008064888A1 (fr) | 2006-11-30 | 2008-06-05 | Glycan-Pharma Switzerland Sa | Procédé de création d'énergie par traitement au plasma de métaux, de sels de métal et d'éléments chimiques non métalliques, et dispositif pour la mise en œuvre de ce procédé |
US20180073361A1 (en) | 2016-09-09 | 2018-03-15 | Christian Daniel Assoun | Plasmas for extraterrestrial resources and applied technologies (pert) space debris remediation, mining, and refining |
-
2019
- 2019-06-19 LU LU101272A patent/LU101272B1/en active IP Right Revival
-
2020
- 2020-04-07 IE IE20200056U patent/IE20200056U1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996023089A1 (fr) | 1993-07-23 | 1996-08-01 | Jolinon Monique | Procede de preparation de complexes organometalliques, les applications en tant que medicaments et en catalyses chimiques |
WO2008055684A1 (fr) | 2006-11-08 | 2008-05-15 | Glycan-Pharma (Switzerland) Sa | Procédé de traitement de déchets dangereux utilisant un plasma et dispositif de mise en œuvre du procédé |
WO2008064888A1 (fr) | 2006-11-30 | 2008-06-05 | Glycan-Pharma Switzerland Sa | Procédé de création d'énergie par traitement au plasma de métaux, de sels de métal et d'éléments chimiques non métalliques, et dispositif pour la mise en œuvre de ce procédé |
US20180073361A1 (en) | 2016-09-09 | 2018-03-15 | Christian Daniel Assoun | Plasmas for extraterrestrial resources and applied technologies (pert) space debris remediation, mining, and refining |
Non-Patent Citations (27)
Title |
---|
AKASSOGLOU KAGALLIU DCHANG CJDAVALOS DGRUTZENDLER JHILLMAN EMCKHAKH BSKLEINFELD DMCGAVERN DBNELSON SJ: "Neurovascular and Immuno-Imaging: From Mechanisms to Therapies", PROCEEDINGS OF THE INAUGURAL SYMPOSIUM. FRONT NEUROSCI, vol. 10, 2016, pages 46 |
BLOOD FLOW METAB, vol. 31, 2011, pages 795 - 806 |
CARCINOGENESIS, vol. 31, no. 1, 29 October 2009 (2009-10-29), pages 59 - 70 |
CHEN BRKOZBERG MGBOUCHARD MBSHAIK MAHILLMAN EMC: "A critical role for the vascular endothelium in functional neurovascular coupling in the brain", JAHA, vol. 3, 2014, pages e000787 |
ELSEVIER CARBOHYDRATE RESEARCH, vol. 172, no. 1-15, January 1988 (1988-01-01), pages 1 - 10 |
GEESINKMEIJER, NEUROQUANTOLOGY, vol. 14, no. 1, March 2016 (2016-03-01), pages 106 - 125 |
HILLMAN EMC: "Out for Blood", SCIENTIFIC AMERICAN MIND, July 2014 (2014-07-01) |
HILLMAN EMCAMOOZEGAR CBWANG TMCCASLIN AFHBOUCHARD MBMANSFIELD JRLEVENSON RM: "In-vivo optical imaging and dynamic contrast methods for biomedical research", PHIL. TRANS. ROYAL SOC A., vol. 369, no. 1955, 2011, pages 4620 - 4643 |
KOZBERG MCHEN BRBOUCHARD MBHILLMAN EMC: "Resolving the transition from negative to positive BOLD in the developing brain", PNAS, vol. 110, no. 11, 2013, pages 4380 - 5 |
LILI ZHANGXIANG ZOUBOHAN ZHANG, LIYUAN CUI, JIAYI ZHANGYING MAOLIANG CHENMINBIAO JI, LABEL-FREE IMAGING OF HEMOGLOBIN DEGRADATION AND HEMOSIDERIN FORMATION IN BRAIN TISSUES WITH FEMTOSECOND PUMP-PROBE MICROSCOPY |
M. GRANDIC. ASSOUNR.A.CANUTOP. COURRIEREP.SOULAM.MAGIORRAA. LACIVITA: "Zn FLNT4", XVI INTERNATIONAL CANCER CONGRESS, 1994 |
M.GRANDIC.ASSOUNM.MAGGIORAG.NUMICOR.CANUTOP. COURRIERP.SOULA, ADVANCES IN MANAGEMENT OF MALIGNANCIES, 6 December 1993 (1993-12-06) |
MA YSHAIK MAKIM SHKOZBERG MGTHIBODEAUX DNZHAO HTYU H.HILLMAN EMC: "Wide-field optical mapping of neural activity and brain haemodynamics: considerations and novel approaches", PHILOS TRANS R SOC LOND B BIOL SCI., vol. 371, 2016, pages 1705 |
MA YSHAIK MAKOZBERG MGKIM SHPORTES JPTIMERMAN DHILLMAN EMC: "Resting-state hemodynamics are spatiotemporally coupled to synchronized and symmetric neural activity in excitatory neurons", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES. PNAS, vol. 113, no. 52, 2016, pages E8463 - E8471 |
MARCU LHILLMAN EMC: "In vivo Optical Imaging / Intravital Microscopy", J BIOPHOTONICS, vol. 10, no. 6-7, June 2017 (2017-06-01), pages 760 - 761 |
MCCASLIN AFHCHEN BRRADOSEVICH AJCAULI BHILLMAN EMCJ CEREB, IN-VIVO 3D MORPHOLOGY OF ASTROCYTE-VASCULATURE INTERACTIONS IN THE SOMATOSENSORY CORTEX: IMPLICATIONS FOR NEUROVASCULAR COUPLING |
NIDHI SHRIVASTAVDEYU LIJOHN M. ESSIGMANN, CHEMICAL BIOLOGY OF MUTAGENESIS AND DNA REPAIR: CELLULAR RESPONSES TO DNA ALKYLATION, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.ov/pubmed/?term=Essimann%20JM%5BAuthor%5D&cauthor=true&cauthoruid=19875697LU> |
No Search * |
PROF. CHARLES L. LIMOLI: "Department of Radiation Oncology", 11 October 2017, UNIVERSITY OF CALIFORNIA IRVINE, MEDICAL SCIENCES I, article "Adenosine Kinase Inhibition Protects against Cranial Radiation-Induced Cognitive Dysfunction", pages: 92697 - 2695 |
QIU JBAIK ADLU LHILLMAN EMCZHUANG ZDONG CGUO XE: "Theoretical Analysis of Novel Quasi-3D Microscopy of Cell Deformation", CEL. MOL. BIOENG, vol. 5, no. 2, 2012, pages 165 - 172, XP035053270, DOI: doi:10.1007/s12195-011-0218-3 |
RAYSHUBSKIY AWOJTASIEWICZ TJMIKELL CBBOUCHARD MBTIMERMAN DYOUNGERMAN BEMCGOVERN RAOTTEN MLCANOLL, PDMCKHANN II GM: "Direct, intraoperative observation of -0. 1 Hz hemodynamic oscillations in awake human cortex: Implications for fMRf", NEUROLMAGE, vol. 87, 2014, pages 323 - 331, XP028817852, DOI: doi:10.1016/j.neuroimage.2013.10.044 |
RONERT WBRADFORD , DSC HENRY W.ALLEN THE ROBERT W.BRADORD FOUNDATION: "References Oxidology (ROS", CHULA VISTA, 1997 |
SILVIA VANNI MARCO ZATTTONIFABIO MODAGIORGIO GIACCONEFABRIZIO TAGLIAVINI ET AL.: "Hemoglobin mRNA changes in the frontal cortex of patients with neurodegenerative diseases", FRONT NEUROSCIENCES, 2018 |
STELLA GANGERKATHARINA SCHINDOWSKI, TAILORING FORMULATIONS FOR INTRANASAL NOSE-TO-BRAIN DELIVERY, 3 August 2018 (2018-08-03) |
THERANOSTICS 2018, vol. 8, no. 15, 16 July 2018 (2018-07-16), pages 4129 - 4140 |
THERAPEUTIC DELIVERY, vol. 5, no. 6, 2014, pages 709 - 733, ISSN: 2041-5990 |
UTE PANZENBOECKZOLTAN BALAZSANDREA SOVICANDELKO HRZENJAKSANJA LEVAK-FRANKANDREA WINTERSPERGERERNST MALLEWOLFGANG SATTLER: "Institute of Medical Biochemistry and Medical Molecular Biology", 28 August 2002, UNIVERSITY GRAZ, JBC PAPERS IN PRESS, article "ABCA1 and Scavenger Receptor Class B, Type I, Are Modulators of Reverse Sterol Transport at an in Vitro Blood-Brain Barrier Constituted of Porcine Brain Capillary Endothelial Cells" |
Also Published As
Publication number | Publication date |
---|---|
IE20200056U1 (en) | 2023-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Khan et al. | Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer’s disease | |
Li et al. | Intrathecal administration of nanoclusters for protecting neurons against oxidative stress in cerebral ischemia/reperfusion injury | |
Guan et al. | Tumor metabolism‐engineered composite nanoplatforms potentiate sonodynamic therapy via reshaping tumor microenvironment and facilitating electron–hole pairs’ separation | |
Kumar et al. | Malignant gliomas: MR imaging spectrum of radiation therapy-and chemotherapy-induced necrosis of the brain after treatment | |
Zhou et al. | Targeting ferroptosis synergistically sensitizes apoptotic sonodynamic anti-tumor nanotherapy | |
Malouff et al. | Carbon ion radiotherapy in the treatment of gliomas: a review | |
Lin et al. | Human umbilical cord mesenchymal stem cells preserve adult newborn neurons and reduce neurological injury after cerebral ischemia by reducing the number of hypertrophic microglia/macrophages | |
Zhao et al. | MicroRNA-124: a key player in microglia-mediated inflammation in neurological diseases | |
Lee et al. | Agouti related peptide secreted via human mesenchymal stem cells upregulates proteasome activity in an Alzheimer’s disease model | |
Eve et al. | Reduction of microhemorrhages in the spinal cord of symptomatic ALS mice after intravenous human bone marrow stem cell transplantation accompanies repair of the blood-spinal cord barrier | |
Van Genugten et al. | Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice | |
Alvarim et al. | Therapeutics with SPION-labeled stem cells for the main diseases related to brain aging: a systematic review | |
Künkele et al. | Neoadjuvant/adjuvant treatment of high-risk retinoblastoma: a report from the German Retinoblastoma Referral Centre | |
Noll et al. | Neurocognition and health-related quality of life among patients with brain tumors | |
Jeon et al. | Coulomb nanoradiator-mediated, site-specific thrombolytic proton treatment with a traversing pristine Bragg peak | |
Zhou et al. | Prior nasal delivery of antagomiR-122 prevents radiation-induced brain injury | |
LU101272B1 (en) | Route and engineering protocols for alzheimer's disease prevention, treatment and neuronal rebuilding | |
Bhatt et al. | Current clinical trials in amyotrophic lateral sclerosis | |
Li et al. | Albumin-binding photosensitizer capable of targeting glioma via the SPARC pathway | |
Wang et al. | Chemical structure and shape enhance MR imaging-guided X-ray therapy following marginative delivery | |
Sulman et al. | World Cancer Day 2021-perspectives in pediatric and adult neuro-oncology | |
Soffietti et al. | Neurotoxicity from old and new radiation treatments for brain tumors | |
US20210000867A1 (en) | New route and engineering protocols for alzheimers disease prevention, treatment and neuronal rebuilding | |
Hilton et al. | Evidence for decreased copper associated with demyelination in the corpus callosum of cuprizone-treated mice | |
Tracy et al. | Intracerebral nanoparticle transport facilitated by alzheimer pathology and age |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Effective date: 20201228 |
|
NF | Patent restored after lapse |